Data / Companies / BNTX
BioNTech SE · Non-US, files 20-F or 40-F
BNTX-US · CIK 000000null ·
Revenue by quarter
US$ · last 8| Quarter | Revenue | Net income | EPS |
|---|
Newest filings
All 463| Form | Filed | Accepted (ET) | |
|---|---|---|---|
| 6-K | 22 Oct 2026 | 22 Oct, 7:49 AM | |
| 6-K | 19 Oct 2026 | 19 Oct, 7:26 AM | |
| 6-K | 13 Oct 2026 | 13 Oct, 4:08 PM | |
| 6-K | 18 Sep 2026 | ||
| 6-K | 14 Sep 2026 | ||
| 6-K | 28 Aug 2026 | ||
| 6-K | 27 Aug 2026 | ||
| 6-K | 20 Aug 2026 |
Description
- Ticker
- BNTX-US
- Exchange
- Index
- Non-US, files 20-F or 40-F
- Industry
- SIC division
- Manufacturing
- CIK
- 000000null
- LEI
- 894500UZJ5LG1F8J1U58
- FIGI
- BBG00Q70B3V1
- Share class FIGI
- BBG00Q70B4L0
- Fiscal year ends
- Dec
- Filings held
- 463 since 2019
- 8-K events
- 0
- Shares short
- 2.5M, 30 Sep 2026
Financial statements
The income statement, balance sheet and cash flow by year and by quarter, line by line as the company reports them. Each column names the filing it comes from.
| Fiscal period | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
| Source filing | 20-F | 20-F | 20-F/A | 20-F | 20-F | 20-F | 20-F/A | 20-F/A | 20-F/A |
| Filed | 31 Mar 2020 | 30 Mar 2021 | 26 Oct 2022 | 27 Mar 2023 | 20 Mar 2024 | 10 Mar 2025 | 30 Jul 2026 | 30 Jul 2026 | 30 Jul 2026 |
| Revenues | 62M EUR | 128M EUR | 109M EURr | 482M EURr | 18,977M EUR | 17,311M EUR | 3,819M EUR | 2,751M EUR | 2,870M EUR |
| Cost of sales | 9.3M EUR | 14M EUR | 17M EURr | 59M EURr | 2,912M EUR | 2,995M EUR | 600M EUR | 541M EUR | 642M EUR |
| Gross profit | 52M EUR | 114M EUR | 91M EUR | – | – | – | – | – | – |
| Research and development expenses | 86M EUR | 143M EUR | 227M EURr | 645M EURr | 949M EUR | 1,537M EUR | 1,783M EUR | 2,254M EUR | 2,105M EUR |
| Sales and marketing expenses | 6.6M EUR | 3M EUR | 2.7M EURr | 15M EURr | 50M EUR | 60M EUR | 63M EUR | 68M EUR | 110M EUR |
| General and administrative expenses | 24M EUR | 26M EUR | 46M EURr | 94M EURr | 277M EURr | 482M EURr | 495M EUR | 531M EUR | 514M EUR |
| Other operating expenses | 0.3M EUR | 0.7M EUR | 0.7M EURr | 2.4M EURr | 103M EURr | 410M EURr | 293M EUR | 812M EUR | 1,088M EUR |
| Other operating income | 2.3M EUR | 5.4M EUR | 2.7M EURr | 251M EURr | 598M EUR | 815M EUR | 105M EUR | 141M EUR | 185M EUR |
| Operating profit / | -61M EUR | -54M EUR | -182M EURr | -82M EURr | 15,284M EUR | 12,643M EUR | 690M EUR | -1,314M EUR | -1,405M EUR |
| % of revenues | -99.5% | -42.2% | -167.1% | -17.1% | 80.5% | 73.0% | 18.1% | -47.8% | -49.0% |
| Finance income | 2.1M EUR | 8M EUR | 4.1M EURr | 1.6M EURr | 68M EUR | 330M EUR | 520M EUR | 664M EUR | 424M EUR |
| Finance expenses | 26M EUR | 0M EUR | 2M EURr | 65M EURr | 305M EUR | 19M EUR | 24M EUR | 27M EUR | 70M EUR |
| Interest expenses related to lease liabilities | 0.7M EUR | 1.7M EUR | 1.7M EUR | 2M EUR | – | – | – | – | – |
| Profit / before tax | -86M EUR | -48M EUR | -179M EURr | -146M EURr | 15,046M EUR | 12,954M EUR | 1,186M EUR | -678M EUR | -1,051M EUR |
| % of revenues | -139.5% | -37.4% | -165.2% | -30.2% | 79.3% | 74.8% | 31.1% | -24.6% | -36.6% |
| Income taxes | 0M EUR | 0.6M EUR | -0.2M EURr | -161M EUR | 4,754M EUR | 3,520M EUR | 256M EUR | -12M EUR | 85M EUR |
| Net profit / | -86M EUR | -48M EUR | -179M EURr | 15M EURr | 10,293M EUR | 9,434M EUR | 930M EUR | -665M EUR | -1,136M EUR |
| % of revenues | -139.5% | -37.8% | -165.0% | 3.2% | 54.2% | 54.5% | 24.4% | -24.2% | -39.6% |
| Basic and diluted, profit / for the period attributable to ordinary equity holders of the parent | -0.51 | -0.25 | -0.85 | 0.06 | – | – | – | – | – |
| Profit attributable to ordinary equity holders of the parent for basic earnings | -86M EUR | -48M EUR | -179M EURr | 15M EURr | 10,293M EUR | – | 930M EUR | -665M EUR | -1,136M EUR |
| Non-controlling interests | -0.3M EUR | -0.2M EUR | -0.1M EURr | 0M EUR | 0M EUR | – | – | – | – |
| Basic earnings for the period per share | – | – | -0.85 | 0.06 | 42.18 | 38.78 | 3.87 | -2.77 | -4.70 |
| Diluted earnings for the period per share | – | – | -0.85 | 0.06 | 39.63 | 37.77 | 3.83 | -2.77 | -4.70 |
Hover a figure for its source.r restated in a later filing– not reported in that period
Lines in the order and wording of the 20-F/A filed 30 Jul 2026. 89 of 89 subtotals add up to the company's own totals. Newest filing read: 30 Jul 2026.
Free for personal research, with credit (Data by Shikshan Nivesh) and a link. API access, bulk files and commercial use need a licence: the data licence.
Charts
Any figure or ratio in the record, by year, by quarter or on a trailing twelve months, as a value or as growth, against a peer if you like. Hover for the figures.
Revenue · annual · US$
Latest Dec 2025: $2.87B · CAGR 2017–2025: 61.6%
Revenue = rev
Ratios
Every ratio, worked out the same way for every company, by year or on a trailing twelve months. Hover a ratio for its formula.
| Fiscal year ending | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on common equity | – | – | −47.2% | 1.6% | 155.2% | 59.1% | 4.6% | −3.4% | −5.9% |
| Return on assets | – | – | −24.7% | 1.0% | 113.4% | 48.2% | 4.0% | −2.9% | −5.1% |
| Return on capital | – | – | −43.5% | −6.0% | 151.4% | 56.7% | 2.7% | −6.4% | −5.7% |
| Return on invested capital | – | – | 374.8% | −28.9% | 191.8% | 109.0% | 7.1% | −13.8% | −10.2% |
| Gross margin | 84.9% | 89.3% | 84.0% | 87.7% | 84.7% | 82.7% | 84.3% | 80.3% | 77.6% |
| EBITDA margin | −82.4% | −25.0% | −135.9% | −9.1% | 80.9% | 73.7% | 22.9% | −36.9% | −35.6% |
| Operating margin | −99.5% | −42.2% | −167.1% | −17.1% | 80.5% | 73.0% | 18.1% | −47.8% | −49.0% |
| Incremental operating margin | – | 11.3% | 672.7% | 26.5% | 83.1% | 158.5% | 88.6% | 187.7% | −76.3% |
| Pretax margin | −139.5% | −37.4% | −165.2% | −30.2% | 79.3% | 74.8% | 31.1% | −24.6% | −36.6% |
| Profit margin | −139.1% | −37.6% | −164.9% | 3.2% | 54.2% | 54.5% | 24.4% | −24.2% | −39.6% |
| Net income to common margin | −139.1% | −37.6% | −164.9% | 3.2% | 54.2% | 54.5% | 24.4% | −24.2% | −39.6% |
| Effective tax rate | −0.1% | −1.3% | 0.1% | 110.4% | 31.6% | 27.2% | 21.6% | 1.8% | −8.1% |
| Dividend payout ratio | – | – | – | 0.0% | 0.0% | 5.1% | 0.0% | 0.0% | – |
| Sustainable growth rate | – | – | – | 1.6% | 155.2% | 56.0% | 4.6% | −3.4% | – |
What the company said with its results
The key points, guidance and management's own words from each of the last four results releases.
No results summary read for this company yet.
Revenue by segment
As the company reports it in the segment note of each annual report: by business, by product and by region, latest year.
This company reports no segment split in its annual report.
Company events
Every 8-K, sorted by the event it reports, with the moment the SEC accepted it in New York time.
No 8-K events held for this company yet.
Every filing
The company's filings with the SEC, newest first: 463 held. Insider, fund and large-holder filings have their own tables below.
| 22 Oct 2026 | 6-K | 22 Oct 2026 | 22 Oct, 7:49 AM ET | |
| 19 Oct 2026 | 6-K | 19 Oct 2026 | 19 Oct, 7:26 AM ET | |
| 13 Oct 2026 | 6-K | 13 Oct 2026 | 13 Oct, 4:08 PM ET | |
| 18 Sep 2026 | 6-K | 18 Sep 2026 | ||
| 14 Sep 2026 | 6-K | 14 Sep 2026 | ||
| 28 Aug 2026 | 6-K | 28 Aug 2026 | ||
| 27 Aug 2026 | 6-K | 27 Aug 2026 | ||
| 20 Aug 2026 | 6-K | 20 Aug 2026 | ||
| 4 Aug 2026 | 6-K | 30 Jun 2026 | ||
| 4 Aug 2026 | 6-K | 4 Aug 2026 | ||
| 3 Aug 2026 | 6-K | 3 Aug 2026 | ||
| 30 Jul 2026 | 20-F/A | 31 Dec 2025 | ||
| 29 Jul 2026 | 6-K | 29 Jul 2026 | ||
| 8 Jun 2026 | 6-K | 8 Jun 2026 | ||
| 1 Jun 2026 | 6-K | 1 Jun 2026 | ||
| 22 May 2026 | 6-K | 22 May 2026 | ||
| 15 May 2026 | 6-K | 15 May 2026 | ||
| 7 May 2026 | 6-K | 7 May 2026 | ||
| 5 May 2026 | 6-K | 31 Mar 2026 | ||
| 5 May 2026 | 6-K | 5 May 2026 | ||
| 13 Apr 2026 | 6-K | 13 Apr 2026 | ||
| 2 Apr 2026 | 6-K | 2 Apr 2026 | ||
| 1 Apr 2026 | 20-F/A | 31 Dec 2025 | ||
| 24 Mar 2026 | 6-K | 24 Mar 2026 | ||
| 10 Mar 2026 | 20-F | 31 Dec 2025 | ||
| 10 Mar 2026 | 6-K | 10 Mar 2026 | ||
| 10 Mar 2026 | 6-K | 10 Mar 2026 | ||
| 28 Jan 2026 | 6-K | 28 Jan 2026 | ||
| 14 Jan 2026 | 6-K | 13 Jan 2026 | ||
| 12 Jan 2026 | 6-K | 12 Jan 2026 | ||
| 6 Jan 2026 | 6-K | 6 Jan 2026 | ||
| 18 Dec 2025 | SC TO-T/A | – | ||
| 18 Dec 2025 | 6-K | 18 Dec 2025 | ||
| 9 Dec 2025 | 6-K | 9 Dec 2025 | ||
| 8 Dec 2025 | 6-K | 6 Dec 2025 | ||
| 3 Dec 2025 | SC TO-T/A | – | ||
| 3 Dec 2025 | 425 | – | ||
| 3 Dec 2025 | 6-K | 3 Dec 2025 | ||
| 26 Nov 2025 | SC TO-T/A | – | ||
| 26 Nov 2025 | 425 | – | ||
| 26 Nov 2025 | 6-K | 26 Nov 2025 | ||
| 12 Nov 2025 | 425 | – | ||
| 12 Nov 2025 | 425 | – | ||
| 12 Nov 2025 | 6-K | 12 Nov 2025 | ||
| 3 Nov 2025 | 6-K | 30 Sep 2025 | ||
| 3 Nov 2025 | 6-K | 3 Nov 2025 | ||
| 22 Oct 2025 | SC TO-T/A | – | ||
| 22 Oct 2025 | 425 | – | ||
| 22 Oct 2025 | 425 | – | ||
| 22 Oct 2025 | 6-K | 22 Oct 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months, with the shares they held after.
| 9 Oct 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 36,209 | $95.37 | $3.5M | 0 | 9 Oct 2026 |
| 8 Oct 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 27,000 | $92.31 | $2.5M | 36,209 | 9 Oct 2026 |
| 7 Oct 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 24,000 | $95.86 | $2.3M | 63,209 | 7 Oct 2026 |
| 6 Oct 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 21,000 | $96.81 | $2.0M | 87,209 | 6 Oct 2026 |
| 5 Oct 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 72,000 | $97.23 | $7.0M | 108,209 | 6 Oct 2026 |
| 2 Oct 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 17,000 | $96.72 | $1.6M | 180,209 | 2 Oct 2026 |
| 1 Oct 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 17,000 | $97.46 | $1.7M | 197,209 | 2 Oct 2026 |
| 30 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 32,000 | $98.12 | $3.1M | 214,209 | 30 Sep 2026 |
| 29 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 34,000 | $98.26 | $3.3M | 246,209 | 30 Sep 2026 |
| 28 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 34,000 | $98.47 | $3.3M | 280,209 | 28 Sep 2026 |
| 25 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 27,000 | $98.69 | $2.7M | 314,209 | 28 Sep 2026 |
| 24 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 39,000 | $98.99 | $3.9M | 341,209 | 24 Sep 2026 |
| 23 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 30,000 | $99.40 | $3.0M | 380,209 | 24 Sep 2026 |
| 22 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 46,000 | $100.72 | $4.6M | 410,209 | 22 Sep 2026 |
| 21 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 33,000 | $97.81 | $3.2M | 456,209 | 22 Sep 2026 |
| 18 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 30,000 | $96.22 | $2.9M | 489,209 | 18 Sep 2026 |
| 17 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 34,000 | $98.60 | $3.4M | 519,209 | 18 Sep 2026 |
| 16 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 15,000 | $96.09 | $1.4M | 553,209 | 16 Sep 2026 |
| 15 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 34,000 | $96.49 | $3.3M | 568,209 | 16 Sep 2026 |
| 14 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 41,000 | $99.45 | $4.1M | 602,209 | 14 Sep 2026 |
| 11 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 45,000 | $96.93 | $4.4M | 643,209 | 14 Sep 2026 |
| 10 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 20,500 | $96.31 | $2.0M | 688,209 | 11 Sep 2026 |
| 9 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 36,000 | $97.78 | $3.5M | 708,709 | 9 Sep 2026 |
| 8 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 37,000 | $99.20 | $3.7M | 744,709 | 9 Sep 2026 |
| 4 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 31,500 | $103.52 | $3.3M | 781,709 | 8 Sep 2026 |
| 3 Sep 2026 | Sahin UgurChief Executive Officer | Sale under a trading plan | 45,000 | $102.85 | $4.6M | 813,209 | 8 Sep 2026 |
| 22 Apr 2026 | Poetting SierkChief Operating Officer | Sale under a trading plan | 50,000 | $110.56 | $5.5M | 399,387 | 23 Apr 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| 3 Sep 2026 | Medine GmbHOfficer, 10% Stockholder | 858,209 | $89.1M | 3 Sep 2026 |
| 12 May 2026 | Medine GmbHOfficer, 10% Stockholder | 858,209 | $80.4M | 13 May 2026 |
| 11 Mar 2026 | Poetting SierkOfficer | 150,000 | $12.6M | 11 Mar 2026 |
| 12 Feb 2026 | Medine GmbHOfficer, 10% Stockholder | 858,209 | $93.9M | 12 Feb 2026 |
| 28 Nov 2025 | Tureci OzlemOfficer | 123,331 | $12.7M | 28 Nov 2025 |
| 13 Nov 2025 | Medine GmbHOfficer, 10% Stockholder | 1,114,130 | $124.4M | 13 Nov 2025 |
| 5 Nov 2025 | Jeggle Helmut WolfgangDirector | 150,000 | $15.5M | 5 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| 15 May 2026 | Medine GmbH | 13G amended | 15.8% | 40.1M |
| 14 May 2026 | ATHOS KG | 13G amended | 40.2% | 101.7M |
Trades by members of the House
From each member's periodic transaction report: the amount is the band the report gives.
| 7 Aug 2025 | Valerie HoyleOR04 | Sale | $1,001 - $15,000 | SP | 12 Sep 2025 |
| 3 Sep 2024 | Josh GottheimerNJ05 | Sale | $1,001 - $15,000 | JT | 3 Oct 2024 |
| 30 Aug 2024 | Josh GottheimerNJ05 | Sale (partial) | $1,001 - $15,000 | JT | 11 Sep 2024 |
| 15 Apr 2024 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 15 May 2024 |
| 14 Mar 2024 | Josh GottheimerNJ05 | Sale | $1,001 - $15,000 | JT | 7 Apr 2024 |
| 6 Dec 2023 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 7 Jan 2024 |
| 5 Dec 2023 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 7 Jan 2024 |
| 7 Dec 2023 | Josh GottheimerNJ05 | Purchase | $1,001 - $15,000 | JT | 7 Jan 2024 |
Short interest
Shares sold short and not yet bought back, on every FINRA settlement date.
| 30 Sep 2026 | 2.5M | +7.49% | 3.12 |
| 15 Sep 2026 | 2.3M | +0.86% | 2.59 |
| 31 Aug 2026 | 2.3M | -8.16% | 1 |
| 14 Aug 2026 | 2.5M | +1.69% | 2.33 |
| 31 Jul 2026 | 2.5M | +8.56% | 3.28 |
| 15 Jul 2026 | 2.3M | -2.28% | 2.91 |
| 30 Jun 2026 | 2.3M | -15.19% | 2.78 |
| 15 Jun 2026 | 2.7M | +21.49% | 2.34 |
| 29 May 2026 | 2.3M | -8.03% | 2.38 |
| 15 May 2026 | 2.5M | +10.73% | 2.6 |
Funds that hold it
Every fund's holding from its latest Form 13F, largest first, with what it added or trimmed in the quarter.
Funds holding
314
quarter to 30 Jun 2026
Added or new
121
since 31 Mar 2026
Trimmed
72
in the quarter
Largest holder
FMR LLC
$704.6M
| FMR LLC | $704.6M | 7.6M | +1.9M | Added | 0.03% | Filing ↗ |
| Primecap Management Co. | $351.0M | 3.8M | -21.7K | Trimmed | 0.21% | Filing ↗ |
| Dodge & Cox | $342.2M | 3.7M | +800 | Held | 0.18% | Filing ↗ |
| Flossbach Von Storch SE | $207.1M | 2.2M | -1.5M | Trimmed | 0.94% | Filing ↗ |
| T. Rowe Price Investment Management, Inc. | $192.2M | 2.1M | -3.8M | Trimmed | 0.13% | Filing ↗ |
| BlackRock, Inc. | $172.6M | 1.9M | +196.8K | Added | 0.00% | Filing ↗ |
| Temasek Holdings (Private) Ltd | $140.1M | 1.5M | 0 | Held | 0.38% | Filing ↗ |
| BNP Paribas Financial Markets | $122.8M | 1.3M | -332.3K | Trimmed | 0.07% | Filing ↗ |
| Logos Global Management LP | $94.4M | 1.0M | +1.0M | New | 4.07% | Filing ↗ |
| GSK plc | $82.8M | 889.8K | 0 | Held | 13.75% | Filing ↗ |
| Assenagon Asset Management S.A. | $78.8M | 846.5K | – | Held | 0.05% | Filing ↗ |
| First Trust Advisors LP | $73.6M | 791.5K | -48.5K | Trimmed | 0.04% | Filing ↗ |
| Davern Capital Partners, LP | $70.2M | 754.5K | +449.5K | Added | 11.97% | Filing ↗ |
| UBS AM, a distinct business unit of UBS Asset Management Americas LLC | $69.2M | 744.2K | -39.8K | Trimmed | 0.01% | Filing ↗ |
| Massachusetts Financial Services Co. | $63.1M | 677.7K | +7.2K | Added | 0.02% | Filing ↗ |
| Long Focus Capital Management, LLC | $58.1M | 624.0K | 0 | Held | 2.37% | Filing ↗ |
| Baillie Gifford & Co. | $55.1M | 592.4K | -290.2K | Trimmed | 0.05% | Filing ↗ |
| Goldman Sachs Group Inc. | $54.9M | 589.9K | +493.1K | Added | 0.01% | Filing ↗ |
| Victory Capital Management Inc. | $50.2M | 539.8K | +62.9K | Added | 0.03% | Filing ↗ |
| Franklin Resources Inc. | $50.2M | 539.6K | +155.0K | Added | 0.01% | Filing ↗ |
| Candriam S.C.A. | $46.3M | 497.5K | +9.2K | Added | 0.21% | Filing ↗ |
| Morgan Stanley | $45.8M | 492.1K | +9.7K | Added | 0.00% | Filing ↗ |
| Bank of America Corp. | $45.2M | 486.2K | -416.8K | Trimmed | 0.00% | Filing ↗ |
| Tang Capital Management LLC | $43.7M | 470.0K | 0 | Held | 2.00% | Filing ↗ |
| Balyasny Asset Management L.P. | $43.1M | 463.2K | +369.7K | Added | 0.08% | Filing ↗ |
| DekaBank Deutsche Girozentrale | $41.2M | 481.4K | 0 | Held | 0.07% | Filing ↗ |
| D. E. Shaw & Co., Inc. | $38.8M | 417.4K | +217.7K | Added | 0.03% | Filing ↗ |
| LBP Am SA | $36.1M | 388.5K | +3.4K | Added | 0.37% | Filing ↗ |
| Marshall Wace, LLP | $35.6M | 382.1K | +133.1K | Added | 0.03% | Filing ↗ |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $35.3M | 379.1K | -8.1K | Trimmed | 0.03% | Filing ↗ |
| Deutsche Bank AG | $35.1M | 377.4K | -14.3K | Trimmed | 0.01% | Filing ↗ |
| Citadel Advisors LLC | $33.9M | 364.6K | -586.8K | Trimmed | 0.02% | Filing ↗ |
| Citigroup Inc. | $33.5M | 359.8K | +49.4K | Added | 0.02% | Filing ↗ |
| SG Americas Securities, LLC | $32.3M | 347.1K | +76.9K | Added | 0.02% | Filing ↗ |
| Point72 Asset Management, L.P. | $30.4M | 327.2K | +327.2K | New | 0.05% | Filing ↗ |
| Legal & General Group Plc | $29.8M | 320.3K | -29.7K | Trimmed | 0.01% | Filing ↗ |
| Two Sigma Investments, LP | $27.2M | 292.6K | +126.4K | Added | 0.02% | Filing ↗ |
| Canada Pension Plan Investment Board | $25.8M | 276.9K | -26.6K | Trimmed | 0.01% | Filing ↗ |
| UBS Group AG | $24.4M | 262.4K | +21.8K | Added | 0.00% | Filing ↗ |
| Hudson Bay Capital Management LP | $24.2M | 260.0K | -15.0K | Trimmed | 0.13% | Filing ↗ |
| CenterBook Partners LP | $23.4M | 251.1K | +79.9K | Added | 1.15% | Filing ↗ |
| Nomura Asset Management International Inc. | $23.2M | 249.4K | -10.3K | Trimmed | 0.04% | Filing ↗ |
| SEB Asset Management AB | $22.8M | 245.1K | +45.0K | Added | 0.09% | Filing ↗ |
| Voloridge Investment Management, LLC | $22.7M | 243.4K | -64.4K | Trimmed | 0.10% | Filing ↗ |
| Charles Schwab Investment Management Inc. | $19.7M | 211.8K | -22.7K | Trimmed | 0.00% | Filing ↗ |
| Squarepoint Ops LLC | $18.5M | 199.0K | +116.2K | Added | 0.04% | Filing ↗ |
| Pictet Asset Management Holding SA | $17.5M | 185.8K | +54.0K | Added | 0.02% | Filing ↗ |
| Groupama Asset Managment | $17.3M | 184.8K | -261 | Trimmed | 0.22% | Filing ↗ |
| Barclays PLC | $17.2M | 184.7K | +32.2K | Added | 0.01% | Filing ↗ |
| TD Asset Management Inc | $16.9M | 181.8K | +22.8K | Added | 0.01% | Filing ↗ |
Dividends and buybacks
Dividend per share, the cash paid and the shares bought back, each fiscal year.
| Dec 2024 | – | $0 | – |
| Dec 2023 | – | $0 | – |
| Dec 2022 | – | $484.3M | – |
| Dec 2021 | – | $0 | – |
| Dec 2020 | – | $0 | – |
Peers
Companies in the same industry, largest first, on the same measures.
| Company | Market value | Revenue, 12 months | Revenue growth | Operating margin | Net margin | ROE | P/E | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|
| BioNTech SEthis company | $22.1B | $3.2B | 4.3% | -49.0% | -39.6% | -5.9% | – | – |
| Amgen Inc. | $237.5B | $38.1B | 9.1% | 30.0% | 23.0% | 74.8% | 27.3× | 19.9× |
| Gilead Sciences, Inc. | $193.7B | $30.5B | 5.5% | -8.2% | -10.6% | -27.4% | – | – |
| Moderna, Inc. | $79.8B | $2.2B | -27.6% | -149.0% | -141.4% | -46.6% | – | – |
| argenx SE | $54.0B | $4.2B | 89.9% | – | – | 17.6% | 44.6× | – |
| Biogen Inc. | $37.1B | $10.0B | 0.3% | 10.1% | 8.3% | 4.4% | 44.4× | 23.7× |
| Exelixis, Inc. | $16.1B | $2.4B | 9.2% | 39.9% | 35.3% | 46.7% | 20.3× | 15.8× |
| Neurocrine Biosciences Inc. | $14.5B | $3.4B | 34.4% | 23.6% | 20.9% | 19.1% | 20.9× | 16.8× |
| Halozyme Therapeutics, Inc. | $14.3B | $1.7B | 41.2% | 35.9% | 24.9% | 288.1% | 37.5× | 26.6× |
| Bio-Techne Corp. | $11.3B | $1.2B | -0.4% | 20.7% | 15.0% | 8.6% | 63.1× | 32.2× |
| Repligen Corp. | $10.0B | $785.1M | 16.5% | 8.2% | 5.3% | 2.0% | 242.1× | 69.2× |
What the company does
BioNTech is a German immunotherapy company best known for the COVID-19 vaccine Comirnaty, and its primary focus now is oncology. It was founded and incorporated on 2 June 2008 as Petersberg 91, V AG, a German stock corporation, renamed BioNTech AG that December, and converted to a European stock corporation called BioNTech SE on 8 March 2019. Its principal executive offices are at An der Goldgrube 12 in Mainz in Germany. It completed its initial public offering in October 2019, the depositary shares are listed on the Nasdaq Global Select Market, and it reports in euros.
Comirnaty
Comirnaty, developed in 2020 with Pfizer, was the first-ever approved mRNA-based product. As of March 2026 the company's COVID-19 vaccine products had been authorised, approved for emergency or temporary use, or granted marketing authorisation in more than 180 countries and regions, and over 5 billion doses had been shipped globally. BioNTech is the Marketing Authorization Holder in the United States, the European Union, the UK, Canada and other countries. Pfizer has marketing and distribution rights worldwide apart from Greater China, Germany and Türkiye, BioNTech holds them in Germany and Türkiye, and under a separate collaboration Fosun Pharma holds them in Mainland China, Hong Kong Special Administrative Region, Macau SAR and the Taiwan region. The variant-adapted vaccine for the 2025/2026 vaccination season launched in 69 markets, and the company reports a market share of over 50% during the fall 2025 vaccination season.
Free for your personal research, with credit and a link. For API access, bulk files or commercial use, tell us what you need. The data licence